DELFI Diagnostics Licenses GEMINI Technology from Johns Hopkins University: Study Demonstrates High Performance for Early Stage Lung Cancer Detection When Integrated with DELFI Diagnostics’s Platform

BALTIMORE and PALO ALTO, Calif., July 27, 2023 /PRNewswire/ — DELFI Diagnostics, a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has exclusively licensed a new, highly accurate method for identifying…

Click here to view original post